The use of a point of care device for monitoring the bone resorption biomarker urinary N-telopeptide in cancer patients with bone metastases

被引:4
|
作者
Lester, Jim E. [1 ]
Brown, Janet E. [2 ]
Hannon, Rosemary A. [3 ]
Ellis, Sue P. [1 ]
Horsman, Janet M. [1 ]
Purohit, Omprakash P. [1 ]
Coleman, Robert E. [1 ]
机构
[1] Weston Pk Hosp, Canc Res Ctr, Acad Unit Clin Oncol, Sheffield S10 2SJ, S Yorkshire, England
[2] St James Univ Hosp, Canc Res UK Clin Ctr Leeds, Leeds LS9 7TF, W Yorkshire, England
[3] No Gen Hosp, Acad Unit Bone Metab, Sheffield S5 7AU, S Yorkshire, England
关键词
Bone; Metastasis; N-telopeptide; POCD; Bisphosphonates; ZOLEDRONIC ACID; BREAST-CANCER; SKELETAL COMPLICATIONS; OSTEOCLAST ACTIVITY; ELEVATED MARKERS; PROSTATE-CANCER; LUNG-CANCER; NTX; SURVIVAL; DISEASE;
D O I
10.1016/j.bone.2009.11.016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type I collagen is the major constituent of bone and its breakdown products are increasingly used as sensitive markers of bone resorption. The N-terminal peptide-bound crosslinks of type I collagen (NTX) can be measured in urine and is useful for the monitoring of patients with metastatic bone disease. Studies have shown that raised NTX levels in metastatic bone disease correlate with an increased risk of complications and pathological fracture. The development of accurate and instantaneous point of care devices (POCD) Would facilitate patient treatment and avoid delays in awaiting results from specialist laboratories. This study assesses the clinical performance of a single use POCD (OSTEOMARK (R) NTx Point of Care Rx Home Use) to monitor NTX levels in patients with metastatic bone disease. NTX was measured in duplicate in 436 urine samples from patients attending clinic with metastatic bone disease using the POCDs. In our centre the frequency of bisphosphonate treatment is dependent on the NTX level, which is categorised into three groups (0-50, 50-100 and > 100 mmol BCE/mmol creatinine). We used these categories to compare the clinical performance of the POCDs to that of a laboratory immunoassay.. From a total of 272 devices, 23 1 (84.9%) successfully recorded a value in nM BCE/mM creatinine. Statistical analysis of the measure of agreement between POCD and laboratory assay found moderate agreement between the two assays (kappa 0.508). Out of the 72 samples with a laboratory assay value of <50, 53 (73.6%) were found to be within the same group recorded by POCD. From the 20 samples with a laboratory assay value of > 100, 19 (95.0%) were found to be within the same category using POCDs. The measurement of urinary NTX by POCD appears to be a viable option for the monitoring of metastatic cancer patients. Whilst POCDs appear to record higher values than laboratory assays, the correlation between devices is good and with further research the NTX categories could be modified to accommodate this variation. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:801 / 805
页数:5
相关论文
共 50 条
  • [1] Urinary crosslinked N-telopeptide of type I collagen and crosslaps as markers of bone resorption in patients with Paget's disease of bone
    Iqbal, SJ
    Whittaker, P
    Davies, T
    [J]. BONE, 1999, 24 (05) : 52S - 52S
  • [2] Preliminary investigation of urine N-telopeptide concentration as a biomarker of bone resorption in dogs receiving glucocorticoids
    Adamany, J. L.
    Cross, G. F.
    Gardner, D.
    Dunning, M. D.
    [J]. JOURNAL OF SMALL ANIMAL PRACTICE, 2017, 58 (07) : 403 - 407
  • [3] Relationship between serum N-telopeptide and bone alkaline phosphatase and their diagnostic value in patients with breast cancer and bone metastases
    Lumachi, F.
    Camozzi, V.
    Luisetto, G.
    Orlando, R.
    Basso, S. M. M.
    Basso, U.
    Cappelletti, P.
    [J]. BONE, 2011, 48 (01) : S25 - S25
  • [4] Prognostic value of urinary N-telopeptide (uNTx) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases
    Rajpar, S.
    Laplanche, A.
    Tournay, E.
    Massard, C.
    Gross-Goupil, M.
    Fizazi, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] VALUE OF BONE RESORPTION MARKER N-TELOPEPTIDE CROSSLINKS IN PREDICTING SKELETAL RELATED EVENTS AND RESPONSE TO ZOLEDRONIC ACID IN BONE METASTASES
    Kamal, N. S.
    Metnawi, W. E.
    Hamada, E.
    Attar, I. E.
    Azim, H. A.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 75 - 75
  • [6] Utility of urinary type I collagen cross-linked N-telopeptide as a prognostic indicator in breast cancer patients with bone metastases
    Masato Shizuku
    Masahiro Shibata
    Mai Okumura
    Dai Takeuchi
    Toyone Kikumori
    Yutaka Mizuno
    [J]. Breast Cancer, 2020, 27 : 1065 - 1071
  • [7] Normalization of urinary N-telopeptide levels by zoledronic acid correlates with improved survival in patients with bone metastases from breast cancer.
    Lipton, A
    Hei, YJ
    Coleman, RE
    Major, P
    Smith, M
    Cook, RJ
    Milton, S
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S129 - S129
  • [8] Utility of urinary type I collagen cross-linked N-telopeptide as a prognostic indicator in breast cancer patients with bone metastases
    Shizuku, Masato
    Shibata, Masahiro
    Okumura, Mai
    Takeuchi, Dai
    Kikumori, Toyone
    Mizuno, Yutaka
    [J]. BREAST CANCER, 2020, 27 (06) : 1065 - 1071
  • [9] Serum cross-linked N-telopeptide of type I collagen as a biomarker of bone metastases for patients with lung cancer: a meta-analysis
    Zhang, Yu
    Yan, Shaohui
    Su, Yanjun
    Chen, Hui
    Wang, Shengguang
    Sun, Bingsheng
    Zhang, Lei
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (12): : 12864 - 12869
  • [10] Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer
    Rajpar, S.
    Massard, C.
    Laplanche, A.
    Tournay, E.
    Gross-Goupil, M.
    Loriot, Y.
    Di Palma, M.
    Bossi, A.
    Escudier, B.
    Chauchereau, A.
    Fizazi, K.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 (09) : 1864 - 1869